Delayed onset panuveitis following intravitreal aflibercept injection

Aflibercept has been listed on the Australian Pharmaceutical Benefit Scheme for the past year for neovascular age-related macular degeneration. Since that time there have not been any reports of delayed onset panuveitis. We present two cases of anterior and posterior uveitis that have occurred 4 wee...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2014-06, Vol.2014, p.bcr2013202515
Main Authors: Glading, Jodi A, Lake, Stewart R, Craig, Jamie E, Supramaniam, Devaraj
Format: Article
Language:English
Subjects:
80 Years
Aged
Aged, 80 and over
Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - adverse effects
Antigens
Australasia
Cataracts
Female
Glaucoma
Herpes viruses
Humans
Inflammation
Injections
Intravitreal Injections
Iodine
Macular degeneration
Macular Degeneration - drug therapy
Male
Panuveitis - chemically induced
Receptors, Vascular Endothelial Growth Factor - administration & dosage
Receptors, Vascular Endothelial Growth Factor - adverse effects
Recombinant Fusion Proteins - administration & dosage
Recombinant Fusion Proteins - adverse effects
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Vascular endothelial growth factor
Visual acuity
White
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aflibercept has been listed on the Australian Pharmaceutical Benefit Scheme for the past year for neovascular age-related macular degeneration. Since that time there have not been any reports of delayed onset panuveitis. We present two cases of anterior and posterior uveitis that have occurred 4 weeks or more after first intravitreal injection of aflibercept. Both patients had received other vascular endothelial growth factor inhibitors prior to aflibercept administration without signs of inflammation and both cases had sterile endophthalmitis. On resolution of the inflammation the patients were recommenced on ranibizumab without further incident.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2013-202515